10 led us to investigate the feasibility of early discharge and outpatient follow-up. High-dose chemotherapy (HDCT) followed by autologous blood cell (ABC) transplantation has been used Accordingly, a three-step approach was planned and executed. The results of this study are reported here. widely for patients with metastatic breast cancer (MBC). It has been shown by our group and others to be an effective means of achieving very high response rates including complete remission. Therefore, further
biotic, antifungal and virustatic drugs. In the event of febrile neutropenia, a standard evaluation and treat-
The HDCT consisted of cyclophosphamide (CY) 6 mg/m 2 ; mitoxantrone 70 mg/m 2 ; and one of the following ment was used. Only 22 patients were admitted for febrile neutropenia and two for haemorrhage. The three drugs: vinblastine 12 mg/m 2 , carboplatin 800 mg/m 2 , or paclitaxel between 250-400 mg/m 2 . This high-dose treatmedian hospital stay was 2 days (range 1-7). The time to engraftment, need for transfusion and other toxicities ment was delivered on 4 consecutive days. After a day of rest, the ABCs were prepared as previously described and were not different in patients who stayed entirely as outpatients. No toxic deaths occurred. In conclusion, reinfused. 10 Since the introduction of DMSO depletion, 11 the nausea, vomiting, and cardiovascular symptoms during HDCT followed by ABC transplantation can be safely administered to patients in the clinic with outpatient and after transplantation, have almost entirely disappeared. When we began using recombinant human granulocyte colpost-transplant observation. Keywords: high-dose chemotherapy; breast cancer; outony-stimulating factor (rhG-CSF) instead of recombinant human granulocyte-macrophage colony-stimulating factor patient transplantation (rhGM-CSF), no growth factor-induced fever was observed. 12 The haematologic recovery after reinfusion of ABC was supported by administration of 5 g/kg of body Over 1000 deaths from breast cancer can be expected in weight rhG-CSF s.c. once a day. 13 All patients received the Canada in 1996 in patients under the age of 55 years.
1 Less HDCT on 4 consecutive days in hospital without any isothan 20% of all patients are alive 3 years after the diagnosis lation procedures. A central line used for administration of of metastatic disease. The median survival time for patients all i.v. drugs and fluids was removed immediately followwho have either hormone receptor negative tumours or who ing the reinfusion of the autograft. have failed hormone therapy, remains between 15 and 18
Following a prospectively outlined three-step approach, months.
2,3 Studies of dose escalation of cytotoxic drugs we initiated the following outpatient follow-up.
Step 1: if with growth factor and/or stem cell support (from the bone patients were stable on day +6, they were discharged to the marrow or peripheral blood) have shown higher response outpatient lodge adjacent to the hospital and followed daily rates, including complete remissions, 4-9 than conventional in the clinic; step 2: patients were discharged on day +1, therapy. The relative low toxicity of HDCT and autologous and in step 3, on day −1. Patients had to be accompanied by a spouse, close friend or a family member; this was mandatory and no exceptions were permitted. A consent other complications, readmission to the hospital was pre- (8 patients) arranged without necessitating emergency room assessment
or registration. At least two peripheral vein blood cultures (13 patients) and urine specimens for microbiology were taken and Phase III 13 Bleeding: 2 1 (0-2) empiric antibiotic therapy was immediately started using (30 patients) 2 g ceftriaxone i.v. q 24 h and tobramycin 5 mg/kg BW i.v. were again discharged to the lodge and the antibiotic treatment was delivered as an outpatient. Complications other
The numbers represent the patients who fulfilled the criteria for neutropenic fever as described in Materials and methods. Each patient who had than febrile neutropenia were dealt with according to clinian episode of fever had only one episode of febrile neutropenia. The days cal circumstances. The supportive therapy requirements set in hospital are shown as a median, with the range in brackets.
as a standard for the outpatient assessment were as follows. Patients were assessed daily by a physician and a nurse in the clinic. Daily blood cell count was done, growth factor platelets and packed red blood cells). Thus, out of our 51 self-administration was taught and information about potenpatients, 22 were readmitted for febrile neutropenia and tial complications and side-effects were repeatedly given.
another two for bleeding disorders. No toxic deaths The staff in the lodge were advised to contact the medical occurred and other non-haematologic toxicity was mild and oncologist on call for potential readmissions. Since our reversible. Only grade II mucositis was observed in our approach was cautious, a single measurement of a temperapatients; the haematologic support is summarized in ture of у38.5°C led to immediate readmission to hospital. Table 2 . The number of platelet transfusions was 0 to 5 and All other unexpected toxicities and side-effects, such as between 0 to 3 units of packed red blood cells were transmacro-haematuria, vaginal bleeding, uncontrolled nausea fused (see Table 2 ). Table 3 shows the haematologic recovand vomiting, severe uncontrolled diarrhea were also ery from the day of reinfusion of the ABC as measured by reasons for immediate readmission.
white blood cells (WBC), absolute neutrophil count (ANC) The endpoint of our study was to show the safety and and platelet number. We also calculated the average numfeasibility of outpatient observation. To exclude a random ber of days in hospital saved by our approach. Each patient chance of events, a minimal number of seven patients per was expected to spend 18 days in hospital; therefore, 918 cohort was chosen. In addition, a comparison was made days in hospital were expected for these 51 patients under between the groups of patients who did and did not require normal circumstances. Eight patients spent only 12 days readmission to hospital to identify differences in in hospital (phase I); 13 patients only 7 days in hospital engraftment times, complication rates, side-effects, and the (phase II), and 30 patients, only 5 days in hospital therapeutic interventions needed. Statistical analysis was (phase III); for a total of 337 days. Twenty-four patients performed using the two-tailed Student's t-test for were readmitted for an average of 2 days for a total of 48 unpaired values.
days. Therefore, the total number of days in hospital was 385 days, giving a calculated saving of 533 days for a total of 10 days per patient.
Results
Of the 53 patients enrolled in this feasibility study, two were not discharged from hospital, due to their reluctance.
Table 2
Haematologic support during the pancytopenic phase after HDCT and ABC infusion
The other 51 patients were discharged in the company of a cooperative care giver who consented to participate. were discharged 1 day after transplantation, seven out of (13 patients) 13 were readmitted with febrile neutropenia; the median Phase III 2 (1-4) 1 (0-3) time spent in hospital after readmission was 2 days (range (30 patients) 1-3). In phase III, 30 patients were discharged prior to ABC transplantation; 13 were readmitted with febrile neu-
Platelets transfused PRBC transfused
The episodes of platelet transfusion and the number of red blood cell tropenia; and two were admitted with bleeding (one nose transfusions in the three individual phases are given as the median with the range in brackets.
bleed and one colorectal bleed requiring transfusion of Blood cell transplantation: outpatient approach S Glück et al 433 Table 3 Haematologic recovery in days after reinfusion of the ABC autograft Values are the median number of days with the range in brackets.
Discussion been evaluated. 24 Also, treatment of febrile neutropenic patients as outpatient cases has been attempted. 25 All these investigators showed that follow-up after HDCT and ABC This paper reports our experience of 51 consecutive patients managed in a step-wise approach to a safe and transplant as well as treatment of complications is possible to some extent on an outpatient basis. Nevertheless, no proeffective outpatient transplantation setting. When we first contemplated this approach, we identified five reasons for spective study has yet been reported showing the feasibility and safety of such an approach. Although, not formally surhospitalization: (1) the administration of HDCT may cause immediate problems such as nausea and vomiting, leading veyed, most of our patients preferred the outpatient approach; those who had to be readmitted, were happier to serious complications (eg dehydration); (2) appropriate hydration and regular administration of mesna is required after being discharged again on i.v. antibiotics. Since further studies are necessary to establish the role of HDCT continuously for 4 days; (3) toxicity can be expected during and after the reinfusion of an autograft that is cryopreserved in patients with MBC, 26 we estimate the number of days in hospital saved by our study to be approximately 10 per in 10% DMSO; (4) febrile neutropenia in the pancytopenic phase after HDCT, is observed in many patients; and patient. From our experience, we believe that a successful approach depends on several essential components: a (5) severe side-effects such as mucositis, profound diarrhea, or significant haemorrhage. Since we introduced autograftnearby lodge or hotel; adequate outpatient facilities; easy access to laboratory and transfusion services; dedicated ing after DMSO depletion in 1993, 11 toxicities due to reinfusion have diminished to a mere aftertaste and a dry nursing staff and the availability of an attending physician. cough. No other side-effects, complications or unexpected occurrences from ABC reinfusion have been observed since then. Moreover, some episodes of neutropenic fever were Acknowledgements associated with the use of GM-CSF. 12 Following this observation, we switched to rhG-CSF (Neupogen; Amgen, MisWe thank the dedicated nursing staff for sharing the clinical sissauga, Ontario, Canada). We have not observed any responsibilities and helping with the patients treatment, thus makhaematopoietic growth factor-induced fever since then.
ing this study possible; Ms Terry Koski, for data collection and Several antibiotics are now available for once daily i.v.
Dr A Gagnon for help and advice in infectiology; Ms Nadia Krane administration. [14] [15] [16] [17] [18] [19] We have used ceftriaxone in combi- transplant has been conducted 23 and supportive care guide-
